Characterization of the SMYD Family of Lysine Methyltransferases: Reflections upon Key Findings and Therapeutic Implications

Author(s): Mark A. Brown, Melissa A. Edwards, Jenna Hoobler

It has been almost two decades since studies upon the SET-MYND (SMYD) family of lysine methyltransferases were first initiated following the serendipitous discovery of the SMYD1 gene. In that time, much has been learned about the roles of the SMYD family in processes ranging from embryogenesis to tumorigenesis. Herein, we reflect upon the implications of the ongoing characterization of the SMYD family with regard to the growing landscape of therapeutic targets.

1. Hwang I and Gottlieb PD. Bop: a new T-cell-restricted gene located upstream of and opposite to mouse CD8b. Immunogenetics. 1995; 42(5): 353-61.
2. Hamamoto R, Furukawa Y, Morita M, Iimura Y, Silva FP, Li M, Yagyu R and Nakamura Y. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells, Nat Cell Biol, 2004; 6: 731-740.
3. Alvarez-Venegas R and Avramova Z. SET-domain proteins of the Su(var)3-9, E(z) and Trithorax families. Gene. 2002; 285: 25-37.
4. Veraksa A, Kennison J, McGinnis W. DEAF-1 function is essential for the early embryonic development of Drosophila. Genesis. 2002; 33:67–76.
5. Spadaccini R, Perrin H, Bottomley MJ, Ansieau S, Sattler M. Structure and functional analysis of the MYND domain. J Mol Biol. 2006; 358:498–508.
6. Liu Y, Cheney MD, Gaudet JJ, Chruszcz M, Lukasik SM, Sugiyama D, Lary J, Cole J, Dauter Z, Minor W, Speck NA, Bushweller JH. The tetramer structure of the Nervy homology two domain, NHR2, is critical for AML1/ETO's activity. Cancer Cell. 2006; 9:249–60.
7. Gottlieb PD, Pierce SA, Sims RJ, Yamagishi H, Weihe EK, Harriss JV, Maika SD, Kuziel WA, King HL and Olson EN. Bop encodes a muscle-restricted protein containing MYND and SET domains and is essential for cardiac differentiation and morphogenesis. Nat. Genet. 2002; 31: 25–32.
8. Tan X, Rotllant J, Li H, de Deyne P and Du SJ. SmyD1, a histone methyltransferase, is required for myofibril organization and muscle contraction in zebrafish embryos. Proc. Natl. Acad. Sci. 2006; 103: 2713–2718.
9. Sirinupong N, Brunzelle J, Ye J, Pirzada A, Nico L and Yang Z. Crystal structure of cardiac specific histone methyltransferase SmyD1 reveals unusual active site architecture. J. Biol. Chem. 2010; 285: 40635–40644.
10. Brown MA, Sims RJ, Gottlieb PD and Tucker PW. Identification and characterization of Smyd2: A split SET/MYND domain-containing histone H3 lysine 36-specific methyltransferase that interacts with the Sin3 histone deacetylase complex. Mol. Cancer. 2006; 5: 26.
11. Diehl F, Brown MA, van Amerongen MJ, Novoyatleva T, Wietelmann A, Harriss J, Ferrazzi F, Böttger T, Harvey RP, Tucker PW and Engel FB. Cardiac deletion of Smyd2 is dispensable for mouse heart development. PLoS One. 2010; 5:3.
12. Wang L, Li L, Zhang H, Luo X, Dai J, Zhou S, Atadja P, Lu C, Li E and Zhao K. Structure of Human SMYD2 Protein Reveals the Basis of p53 Tumor Suppressor Methylation. J. Biol. Chem. 2011; 286:38725–37.
13. Jiang Y, Sirinupong N, Brunzelle J and Yang Z. Crystal Structures of Histone and p53 Methyltransferase SmyD2 Reveal a Conformational Flexibility of the Autoinhibitory C-Terminal Domain. PLoS ONE. 2011; 6:e21640.
14. Foreman KW, Brown M, Park F, Emtage S, Harriss J, Das C, Zhu L, Crew A, Arnold L, Shaaban S and Tucker P. Structural and Functional Profiling of the Human Histone Methyltransferase SMYD3. PLoS ONE. 2011; 6:1–12.
15. Van Aller GS, Reynoird N, Barbash O, Huddleston M, Liu S, Zmoos AF, McDevitt P, Sinnamon R, Le B, Mas G, Annan R, Sage J, Garcia BA, et al. Smyd3 regulates cancer cell phenotypes and catalyzes histone H4 lysine 5 methylation. Epigenetics. 2012; 7:340–3.
16. Kunizaki M, Hamamoto R, Silva FP, Yamaguchi K, Nagayasu T, Shibuya M, Nakamura Y and Furukawa Y. The Lysine 831 of Vascular Endothelial Growth Factor Receptor 1 is a Novel Target of Methylation by SMYD3. Cancer Research. 2007; 67:10759–65.
17. Silva FP, Hamamoto R, Kunizaki M, Tsuge M, Nakamura Y and Furukawa Y. Enhanced methyltransferase activity of SMYD3 by the cleavage of its N-terminal region in human cancer cells. Oncogene. 2008; 27:2686–92.
18. Hamamoto R, Silva FP, Tsuge M, Nishidate T, Katagiri T, Nakamura Y and Furukawa Y. Enhanced SMYD3 expression is essential for the growth of breast cancer cells. Cancer Sci. 2006; 97:113–8.
19. Tsuge M, Hamamoto R, Silva FP, Ohnishi Y, Chayama K, Kamatani N, Furukawa Y and Nakamura Y. A variable number of tandem repeats polymorphism in an E2F-1 binding element in the 5′ flanking region of SMYD3 is a risk factor for human cancers. Nat Genet. 2005; 37:1104–7.
20. Wang H, Liu Y, Tan W, Zhang Y, Zhao N, Jiang Y, Lin C, Hao B, Zhao D, Qian J, Lu D, Jin L, Wei Q, et al. Association of the variable number of tandem repeats polymorphism in the promoter region of the SMYD3 gene with risk of esophageal squamous cell carcinoma in relation to tobacco smoking. Cancer Sci. 2008; 99:787–91.
21. Sirinupong N, Brunzelle J, Doko E and Yang Z. Structural Insights into the Autoinhibition and Posttranslational Activation of Histone Methyltransferase SmyD3. J Mol Biol. 2011; 406:149–59.
22. Xu S, Wu J, Sun B, Zhong C and Ding J. Structural and biochemical studies of human lysine methyltransferase Smyd3 reveal the important functional roles of its post-SET and TPR domains and the regulation of its activity by DNA binding. Nucleic Acids Research. 2011; 39:4438–49.
23. Brown MA, Foreman K, Harriss J, Das C, Zhu L, Edwards M, Shaaban S, and Tucker H. C-terminal domain of SMYD3 serves as a unique HSP90-regulated motif in oncogenesis. Oncotarget, In Press.
24. Leinhart K and Brown MA. SET/MYND Lysine Methyltransferases Regulate Gene Transcription and Protein Activity. Genes. 2011; 2:210–8.